ARK Diagnostics
ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic assays for therapeutic drug monitoring, serving hospitals, clinical laboratories, and healthcare providers seeking precision dosing and personalized medicine tools. Founded in 2003, the Fremont, CA-based company operates within the global TDM market.
- Company typePrivate
- Founded2003
- HeadquartersFremont, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ARK Diagnostics does
ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic products, with a portfolio centered on diagnostic assays used for therapeutic drug monitoring (TDM). Founded in 2003 and headquartered in Fremont, California, the company develops assays that enable healthcare providers, hospitals, and clinical laboratories to measure and monitor drug levels in patients, supporting personalized medicine and precision dosing workflows. The core technology is chemistry-based in vitro diagnostic assays rather than instrumented platforms, and the company operates within the global TDM market valued at approximately $1.87 billion in 2024 with a 3.92% CAGR projection to ~$2.75 billion by 2034.
The company's revenue model is based on the sale of diagnostic assay products (test kits) to its healthcare and life sciences customer base, with pricing not publicly disclosed. Its go-to-motion targets hospital laboratories and reference labs requiring precision dosing tools, with no AI/ML or software-as-a-service component evident. Prior to October 2025, ARK was majority-owned by South Korean conglomerate Soulbrain Holdings; that month ARCHIMED Diagnostics acquired a 60% controlling stake at a ~$428 million valuation, with stated intent to fund product development, market expansion, and operational scale. Earlier angel capital from Sand Hill Angels (2009, 2012) rounds are also documented.
ARK Diagnostics firmographics
Firmographics- Name
- ARK Diagnostics
- Website
- https://ark-tdm.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic assays for therapeutic drug monitoring, serving hospitals, clinical laboratories, and healthcare providers seeking precision dosing and personalized medicine tools. Founded in 2003, the Fremont, CA-based company operates within the global TDM market.
- Ownership category
- akta.pro rank
ARK Diagnostics industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF)
Keywords
Where ARK Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Fremont
- HQ country
- United States
- HQ region
- North America
Markets served
ARK Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Diagnostic Assay Products: ARK Diagnostics develops and sells diagnostic assay products, likely generating revenue through the sale of diagnostic test kits and related products for therapeutic drug monitoring.
ARK Diagnostics product offering
Product offeringCore offering
ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic assays focused on therapeutic drug monitoring (TDM). Its products enable healthcare providers and clinical laboratories to measure drug levels in patients, supporting precision dosing and personalized medicine.
Product overview
ARK Diagnostics is a developer of diagnostic assays focused on therapeutic drug monitoring (TDM). The company's product portfolio centers on diagnostic assays that enable healthcare providers to measure and monitor drug levels in patients, supporting personalized medicine approaches and precision dosing. The company operates in the broader therapeutic drug monitoring market, which was valued at approximately USD 1870.56 million in 2024 and is forecasted to reach USD 2747.66 million by 2034.
Differentiator
Problem solved
Functional benefit
Products and services
- Diagnostic Assays
Quantifiable outcome
- Global therapeutic drug monitoring market growing at 3.92% CAGR, projected to reach $2.75 billion by 2034
Companies that use ARK Diagnostics
Customer profileSegments1 record
Ideal customer profiles1 record
ARK Diagnostics technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
ARK Diagnostics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Soulbrain HoldingscoreSoulbrain Holdings, a South Korean company, sold its 60% controlling stake in ARK Diagnostics to ARCHIMED Diagnostics as part of a carve-out transaction valued at approximately $428 million.
Scale indicators3 records
Recent moves8 records
Expansion highlights4 records
ARK Diagnostics competitors and assessment
Company assessmentDirect peers
- DiaSorin: DiaSorin is a specialty IVD company focused on immunodiagnostics and molecular diagnostics, with comparable scale and channel profile to ARK and overlapping specialty assay development.
- Saladax Biomedical: Saladax develops immunoassays specifically for therapeutic drug monitoring of antipsychotics and other drugs — the closest direct competitor to ARK's TDM-focused assay portfolio, targeting the same clinical customers.
- QIAGEN: QIAGEN develops molecular and immunoassay diagnostic products for clinical and research labs, with a similar specialty-IVD commercial model and customer overlap in hospital and reference laboratories.
- Hologic: Hologic is a specialty diagnostics company whose clinical diagnostics franchise includes assay development for women's health and infectious disease, with comparable specialty-IVD manufacturing and channel characteristics to ARK.
- Bio-Rad Laboratories: Bio-Rad is a specialty IVD manufacturer with clinical chemistry and immunoassay products; its Life Science and Clinical Diagnostics segments overlap with ARK's reagent/assay manufacturing business model and customer base.
Broad incumbents
- Siemens Healthineers: Siemens Healthineers' Atellica and ADVIA Centaur systems include therapeutic drug monitoring assays as part of their integrated immunoassay/clinical chemistry offerings to large hospital systems.
- Beckman Coulter (Danaher): Beckman Coulter (a Danaher operating company) manufactures automated IVD chemistry and immunoassay systems with TDM-relevant assays, competing with ARK for placement on large hospital and reference-lab platforms.
- Thermo Fisher Scientific: Thermo Fisher (including its Binding Site and specialty diagnostics segments) is a diversified IVD manufacturer serving clinical and research labs, with TDM-related reagents and immunoassay products competing with ARK's portfolio.
- Roche Diagnostics: Roche operates one of the broadest IVD portfolios globally, including therapeutic drug monitoring assays integrated into its cobas automated chemistry/immunoassay platforms used by hospitals and reference labs.
- Abbott Diagnostics: Abbott's ARCHITECT and Alinity platforms include TDM assays alongside a much broader IVD menu; competes with ARK for hospital and reference-lab test volume on automated chemistry/immunoassay systems.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
ARK Diagnostics social profiles
Digital presenceARK Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ARK Diagnostics leadership team
Management profileNumber of profiles
Profiles1 record
ARK Diagnostics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ARK Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ARK Diagnostics
What does ARK Diagnostics do?
ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic assays focused on therapeutic drug monitoring (TDM). Its products enable healthcare providers and clinical laboratories to measure drug levels in patients, supporting precision dosing and personalized medicine.
Is ARK Diagnostics a public or private company?
ARK Diagnostics is a private company. It is classified as private equity controlled and is currently acquired.
When was ARK Diagnostics founded?
ARK Diagnostics was founded in 2003. It employs 11 to 50 people.
Where is ARK Diagnostics based?
ARK Diagnostics is headquartered in Fremont, United States, in the North America region.
How does ARK Diagnostics make money?
One revenue line is on record: diagnostic Assay Products.
Who are ARK Diagnostics's main competitors?
Direct peers on record are DiaSorin, Saladax Biomedical, QIAGEN, Hologic and Bio-Rad Laboratories. Broad incumbents are Siemens Healthineers, Beckman Coulter (Danaher), Thermo Fisher Scientific, Roche Diagnostics and Abbott Diagnostics.
Does ARK Diagnostics have an API?
No public API is recorded for ARK Diagnostics.
What industry is ARK Diagnostics in?
ARK Diagnostics's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAFAMAF, Toxicology & Therapeutic Drug Monitoring Laboratories. Its NAICS code is 325413 and its SIC code is 2835.